These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21527115)

  • 1. The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study.
    Schöndorf T; Musholt PB; Hohberg C; Forst T; Lehmann U; Fuchs W; Löbig M; Müller J; Pfützner A
    J Diabetes Sci Technol; 2011 Mar; 5(2):426-32. PubMed ID: 21527115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
    Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
    Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone--results from a post-marketing surveillance trial under daily routine conditions.
    Schöndorf T; Karagiannis E; Posseldt RE; Forst T; Pfützner A
    Diabetes Technol Ther; 2009 Jun; 11(6):379-83. PubMed ID: 19459767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes.
    Perez A; Jacks R; Arora V; Spanheimer R
    J Clin Hypertens (Greenwich); 2010 Dec; 12(12):973-82. PubMed ID: 21122063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes.
    Genovese S; De Berardis G; Nicolucci A; Mannucci E; Evangelista V; Totani L; Pellegrini F; Ceriello A
    Adv Ther; 2013 Feb; 30(2):190-202. PubMed ID: 23359066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
    Mazzone T; Meyer PM; Feinstein SB; Davidson MH; Kondos GT; D'Agostino RB; Perez A; Provost JC; Haffner SM
    JAMA; 2006 Dec; 296(21):2572-81. PubMed ID: 17101640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials.
    Rajagopalan R; Iyer S; Khan M
    Curr Med Res Opin; 2005 Jan; 21(1):163-72. PubMed ID: 15881488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians.
    Ramachandran A; Snehalatha C; Salini J; Vijay V
    J Assoc Physicians India; 2004 Jun; 52():459-63. PubMed ID: 15645955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
    Vaccaro O; Masulli M; Nicolucci A; Bonora E; Del Prato S; Maggioni AP; Rivellese AA; Squatrito S; Giorda CB; Sesti G; Mocarelli P; Lucisano G; Sacco M; Signorini S; Cappellini F; Perriello G; Babini AC; Lapolla A; Gregori G; Giordano C; Corsi L; Buzzetti R; Clemente G; Di Cianni G; Iannarelli R; Cordera R; La Macchia O; Zamboni C; Scaranna C; Boemi M; Iovine C; Lauro D; Leotta S; Dall'Aglio E; Cannarsa E; Tonutti L; Pugliese G; Bossi AC; Anichini R; Dotta F; Di Benedetto A; Citro G; Antenucci D; Ricci L; Giorgino F; Santini C; Gnasso A; De Cosmo S; Zavaroni D; Vedovato M; Consoli A; Calabrese M; di Bartolo P; Fornengo P; Riccardi G; ;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):887-897. PubMed ID: 28917544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
    Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
    Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes.
    Ceriello A; Johns D; Widel M; Eckland DJ; Gilmore KJ; Tan MH
    Diabetes Care; 2005 Feb; 28(2):266-72. PubMed ID: 15677777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
    DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
    J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study.
    Pfützner A; Marx N; Lübben G; Langenfeld M; Walcher D; Konrad T; Forst T
    J Am Coll Cardiol; 2005 Jun; 45(12):1925-31. PubMed ID: 15963388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions.
    Karagiannis E; Pfützner A; Forst T; Lübben G; Roth W; Grabellus M; Flannery M; Schöndorf T
    Diabetes Technol Ther; 2008 Jun; 10(3):206-12. PubMed ID: 18473695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The comparative effect of pioglitazone and metformin on serum osteoprotegerin, adiponectin and intercellular adhesion molecule concentrations in patients with newly diagnosed type 2 diabetes: a randomized clinical trial.
    Esteghamati A; Azizi R; Ebadi M; Noshad S; Mousavizadeh M; Afarideh M; Nakhjavani M
    Exp Clin Endocrinol Diabetes; 2015 May; 123(5):289-95. PubMed ID: 25607338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).
    Pratley RE; Urosevic D; Boldrin M; Balena R;
    Diabetes Obes Metab; 2013 Mar; 15(3):234-40. PubMed ID: 22958426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.